314930 — Biodyne Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩256bn
- KR₩237bn
- KR₩4bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,089 | 3,671 | 3,763 | 12,210 | 4,089 |
Cost of Revenue | |||||
Gross Profit | 1,175 | 479 | 499 | 9,305 | 684 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 5,787 | 5,497 | 6,106 | 5,527 | 6,139 |
Operating Profit | -1,698 | -1,826 | -2,343 | 6,683 | -2,051 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,469 | -5,060 | -11,138 | 7,366 | -1,221 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,026 | -4,454 | -10,857 | 5,611 | -992 |
Net Income Before Extraordinary Items | |||||
Net Income | -2,026 | -4,454 | -10,857 | 5,611 | -992 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2,026 | -4,454 | -10,857 | 5,611 | -992 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -90.4 | -192 | -367 | 182 | -31 |
Dividends per Share |